![Hong He](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hong He
Net worth: 1 M $ as of 30/12/2025
Profile
Hong He currently works at CytomX Therapeutics, Inc., as Director-Financial Planning & Analysis from 2021 and Power Solutions International, Inc., as Independent Director from 2019.
Mr. He also formerly worked at SciClone Pharmaceuticals LLC, as Finance Director from 2014 to 2018, BlackThorn Therapeutics, Inc., as Director-Finance & Reporting in 2019, Fuling Global, Inc., as Independent Director from 2015 to 2020, GenapSys, Inc., as Head-Finance from 2018 to 2019, Baidu, Inc., as Vice President-Finance from 2011 to 2013, Sunity Online Entertainment Ltd., as Chief Financial Officer from 2010 to 2011, and Augmedix Operating Corp., as Vice President-Finance & Controller in 2014.
Mr. He received his undergraduate degree in 1992 from Beijing University of Technology and Masters Business Admin degree in 2006 from The University of Chicago Booth School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 10/12/2025 | 23,750 ( 0.1% ) | 1 M $ | 30/12/2025 |
Hong He active positions
| Companies | Position | Start |
|---|---|---|
| POWER SOLUTIONS INTERNATIONAL, INC. | Director/Board Member | 13/11/2019 |
| CYTOMX THERAPEUTICS, INC. | Corporate Officer/Principal | 31/01/2020 |
Former positions of Hong He
| Companies | Position | End |
|---|---|---|
| FULING GLOBAL INC. | Director/Board Member | 31/12/2019 |
BlackThorn Therapeutics, Inc.
 BlackThorn Therapeutics, Inc. Manufactures and markets medicines for neuron developmental disorders | Director of Finance/CFO | 30/11/2019 |
GenapSys, Inc.
 GenapSys, Inc. Develops a DNA-sequencing technology that enables fast, accurate, and low cost genetic research & testing services | Corporate Officer/Principal | 30/04/2019 |
| SCICLONE PHARMACEUTICALS, INC. | Director of Finance/CFO | 31/12/2017 |
Augmedix Operating Corp.
 Augmedix Operating Corp. Develops technology platform for healthcare providers | Comptroller/Controller/Auditor | 31/05/2014 |
Training of Hong He
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Develops therapeutics for the treatment of cancer and infectious diseases | |
GenapSys, Inc.
GenapSys, Inc. Develops a DNA-sequencing technology that enables fast, accurate, and low cost genetic research & testing services | |
Baidu, Inc.
 Baidu, Inc. Internet Software/ServicesTechnology Services Provides online marketing, cloud and content distribution services | Technology Services |
Beijing University of Technology
 Beijing University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sunity Online Entertainment Ltd.
 Sunity Online Entertainment Ltd. Develops and operates online games | |
Power Solutions International, Inc.
 Power Solutions International, Inc. Designs, manufactures, distributes and supports power systems for industrial original equipment manufacturers | |
The University of Chicago Booth School of Business
 The University of Chicago Booth School of Business Functions as a College/University | |
Augmedix Operating Corp.
Augmedix Operating Corp. Develops technology platform for healthcare providers | |
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Manufactures and markets medicines for neuron developmental disorders | |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | |
Fuling Global, Inc.
 Fuling Global, Inc. Manufactures plastic and paper disposable products |
- Stock Market
- Insiders
- Hong He
